药物相关性颌骨坏死治疗方法的研究进展

doi:10.19438/j.cjoms.2020.05.017

中国口腔颌面外科杂志 ›› 2020, Vol. 18 ›› Issue (5): 474-477.doi: 10.19438/j.cjoms.2020.05.017

药物相关性颌骨坏死治疗方法的研究进展

姜钧健, 何悦

上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科, 国家口腔疾病临床医学研究中心, 上海市口腔医学重点实验室, 上海市口腔医学研究所,上海 200011

收稿日期:2019-03-29 修回日期:2019-12-20 出版日期:2020-09-20 发布日期:2020-10-28
通讯作者: 何悦,Tel:021-23271699,E-mail: william5218@126.com
作者简介:姜钧健（1993-）,男,硕士研究生,E-mail: jiangjj0104@126.com
基金资助:
国家自然科学基金（81570949）

Research progress on treatment of medication-related osteonecrosis of the jaw

JIANG Jun-jian, HE Yue

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology& Shanghai Research Institute of Stomatology. Shanghai 200011, China;

Received:2019-03-29 Revised:2019-12-20 Online:2020-09-20 Published:2020-10-28

摘要/Abstract

摘要： 药物相关性颌骨坏死是患者使用抗骨吸收或抗血管生成药物导致的并发症,破坏了口腔卫生,影响患者饮食、语音功能,降低生活质量。对MRONJ患者最恰当的治疗策略还未达成共识。本文就近年来药物相关性颌骨坏死的分期及辅助治疗方法的研究进展作一综述。

关键词: 药物相关性颌骨坏死, 双膦酸盐, 分期, 治疗

Abstract: Medication-related osteonecrosis of the jaw is a complication in patients taking antiresorptive or antiangiogenic drugs. It destroys oral hygiene, affects patients' eating, speech and reduces their quality of life. There is no consensus on the most appropriate treatment strategy for medication-related osteonecrosis of the jaw till now. This article summarized the recent research on staging and adjuvant treatment of medication-related osteonecrosis of the jaw.

Key words: Medication-related osteonecrosis of the jaw, Bisphosphonate, Staging, Therapy

中图分类号:

R782.3

姜钧健, 何悦. 药物相关性颌骨坏死治疗方法的研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(5): 474-477.

JIANG Jun-jian, HE Yue. Research progress on treatment of medication-related osteonecrosis of the jaw[J]. China J Oral Maxillofac Surg, 2020, 18(5): 474-477.

参考文献

[1] Stevenson M, Jones ML, De Nigris E, et al.A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis[J]. Health Technol Assess, 2005, 9(22): 1-160.
[2] Marx RE.Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9): 1115-1157.
[3] Greuter S, Schmid F, Ruhstaller T, et al.Bevacizumab-associated osteonecrosis of the jaw[J]. Ann Oncol, 2008, 19(12): 2091-2092.
[4] Koch FP, Walter C, Hansen T, et al.Osteonecrosis of the jaw related to sunitinib[J]. Oral Maxillofac Surg, 2011, 15(1): 63-66.
[5] Owosho AA, Scordo M, Yom SHK, et al.Osteonecrosis of the jaw a new complication related to Ipilimumab[J]. Oral Oncol, 2015, 51(12): e100-101.
[6] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10): 1938-1956.
[7] Allen BW, Demchenko IT, Piantadosi CA.Two faces of nitric oxide: implications for cellular mechanisms of oxygen toxicity[J]. J Appl Physiol(1985), 2009, 106(2): 662-667.
[8] Piantadosi CA, Tatro LG.Regional H₂O₂ concentration in rat brain after hyperoxic convulsions[J]. J Appl Physiol(1985), 1990, 69(5): 1761-1766.
[9] Demchenko IT, Boso AE, O'Neill TJ, et al. Nitric oxide and cerebral blood flow responses to hyperbaric oxygen[J]. J Appl Physiol(1985), 2000, 88(4): 1381-1389.
[10] Demchenko IT, Boso AE, Whorton AR, et al.Nitric oxide production is enhanced in rat brain before oxygen-induced convulsions[J]. Brain Res, 2001, 917(2): 253-261.
[11] Boykin Jr JV, Baylis C.Hyperbaric oxygen therapy mediates increased nitric oxide production associated with wound healing: a preliminary study[J]. Adv Skin Wound Care, 2007, 20(7): 382-388.
[12] Freiberger JJ.Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws[J]. J Oral Maxillofac Surg, 2009, 67(5 Suppl): 96-106.
[13] Freiberger JJ, Padilla-Burgos R, McGraw T, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics[J]. J Oral Maxillofac Surg, 2012, 70(7): 1573-1583.
[14] Delanian S.Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol[J]. Br J Radiol, 1998, 71(848): 892-894.
[15] Delanian S, Depondt J, Lefaix JL.Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase Ⅱ trial[J]. Head Neck, 2005, 27(2): 114-123.
[16] Delanian S, Porcher R, Rudant J, et al.Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis[J]. J Clin Oncol, 2005, 23(34): 8570-8579.
[17] Epstein MS, Wicknick FW, Epstein JB, et al.Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010, 110(5): 593-596.
[18] Magremanne M, Reychler H.Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis[J]. J Oral Maxillofac Surg, 2014, 72(2): 334-337.
[19] Owosho AA, Estilo CL, Huryn JM, et al.Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(4): 455-459.
[20] Ripamonti CI, Cislaghi E, Mariani L, et al.Efficacy and safety of medical ozone (O₃) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase Ⅰ-Ⅱstudy[J]. Oral Oncol, 2011, 47(3): 185-190.
[21] Agrillo A, Filiaci F, Ramieri V, et al.Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy[J]. Eur Rev Med Pharmacol Sci, 2012, 16(12): 1741-1747.
[22] Cheung A, Seeman E.Teriparatide therapy for alendronate-associated osteonecrosis of the jaw[J]. N Engl J Med, 2010, 363(25): 2473-2474.
[23] Dayisoylu EH, Senel FÇ, Üngör C, et al.The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study[J]. Int J Oral Maxillofac Surg, 2013, 42(11): 1475-1480.
[24] Kim KM, Park W, Oh SY, et al.Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw[J]. Osteoporos Int, 2014, 25(5): 1625-1632.
[25] Kakehashi H, Ando T, Minamizato T, et al.Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings[J]. Int J Oral Maxillofac Surg, 2015, 44(12): 1558-1564.
[26] Badran Z, Abdallah MN, Torres J, et al.Platelet concentrates for bone regeneration: Current evidence and future challenges[J]. Platelets, 2018, 29(2): 105-112.
[27] Tsai LL, Huang YF, Chang YC.Treatment of bisphosphonate-related osteonecrosis of the jaw with platelet-rich fibrin[J]. J Formos Med Assoc, 2016, 115(7): 585-586.
[28] Adornato MC, Morcos I, Rozanski J.The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors[J]. J Am Dent Assoc, 2007, 138(7): 971-977.
[29] Curi MM, Cossolin GSI, Koga DH, et al.Bisphosphonate-related osteonecrosis of the jaws-an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma[J]. J Oral Maxillofac Surg, 2011, 69(9): 2465-2472.
[30] Fernando de Almeida Barros Mourão C, Calasans-Maia MD, Del Fabbro M, et al. The use of Platelet-rich fibrin in the management of medication-related osteonecrosis of the jaw: a case series[J]. J Stomatol Oral Maxillofac Surg, 2020, 121(1):84-89.
[31] Giudice A, Barone S, Giudice C, et al.Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2018, 126(5): 390-403.
[32] Nφrholt SE, Hartlev J.Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients[J]. Int J Oral Maxillofac Surg, 2016, 45(10): 1256-1260.

药物相关性颌骨坏死治疗方法的研究进展

Research progress on treatment of medication-related osteonecrosis of the jaw

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王雪, 张宁. 810 nm波长半导体激光治疗口腔黏液腺囊肿的临床疗效观察[J]. 中国口腔颌面外科杂志, 2024, 22(5): 459-462.
[2]	祁庆龙, 余红梅, 潘洋. 2种方法治疗下颌第二磨牙远中牙槽骨吸收的效果比较[J]. 中国口腔颌面外科杂志, 2024, 22(5): 463-467.
[3]	郭毅波, 李晨尧, 樊奇, 季彤, 任振虎. 头颈癌治疗诱发的淋巴水肿：临床因素和预后分析[J]. 中国口腔颌面外科杂志, 2024, 22(4): 360-364.
[4]	郭逸飞, 张永红, 任振虎. 头颈部肉瘤的诊断与治疗现状[J]. 中国口腔颌面外科杂志, 2024, 22(4): 404-408.
[5]	徐晨, 马丽娟, 石尧, 文玉珍, 宋永海, 车宗刚. 腮腺区炎性肌纤维母细胞瘤1例报告及文献复习[J]. 中国口腔颌面外科杂志, 2024, 22(4): 413-416.
[6]	史宣宣, 刘怡然, 石亮, 陈安威, 王涛, 刘少华. 改良DSS法制作稳定泡沫的效果评价[J]. 中国口腔颌面外科杂志, 2024, 22(3): 245-248.
[7]	周循, 索璐璐, 刘锦星, 周徐慧, 仇琳, 李静洁, 郑永超, 劳蔚. 颌面部鲜红斑痣患儿光动力治疗苏醒期躁动的影响因素及药物干预措施的观察性研究[J]. 中国口腔颌面外科杂志, 2024, 22(3): 261-267.
[8]	张芳, 寿卫东, 李妍. 医护协同下聚多卡醇泡沫硬化剂治疗头颈部静脉畸形疗效评价[J]. 中国口腔颌面外科杂志, 2024, 22(3): 274-278.
[9]	王延安, 秦中平, 郑家伟, 李春洁, 刘少华, 杨耀武, 陈刚, 陈伟良, 刘学键, 杜仲, 张雷, 王业飞, 王德明, 苏立新, 谢峰, 董长宪, 郭磊, 李凯, 顾松, 何悦, 张志愿. 头颈部血管瘤及脉管畸形手术治疗专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(2): 105-117.
[10]	石慧烽, 涂文勇, 胡海生, 樊文慧, 毕帆, 劳峥. 非共面照射野在舌癌放疗中对脊髓和下颌骨重点保护的效果评价[J]. 中国口腔颌面外科杂志, 2024, 22(1): 58-62.
[11]	李晓, 王豪伟, 杨西涛, 王德明, 范新东, 苏立新. 颌骨骨内动静脉畸形介入栓塞治疗远期疗效分析[J]. 中国口腔颌面外科杂志, 2024, 22(1): 78-83.
[12]	靳能皓, 田瑜, 朱亮, 乔波, 李粮博, 张海钟, 张蕾. PD-L1及肿瘤免疫微环境对预测口腔鳞癌新辅助治疗效果的意义[J]. 中国口腔颌面外科杂志, 2023, 21(6): 572-578.
[13]	李晨曦, 龚忠诚, 赵化荣, 丁明超, 刘慧. 肿瘤治疗电场在头颈部癌症中的应用前景[J]. 中国口腔颌面外科杂志, 2023, 21(5): 425-431.
[14]	王守鹏, 李胜男, 陈霖, 葛良玉, 李梦, 孟箭. ¹²⁵I放射性粒子植入治疗复发性腭部小唾液腺恶性肿瘤7例临床分析[J]. 中国口腔颌面外科杂志, 2023, 21(5): 497-501.
[15]	宋娇娇, 鲁倩, 曹璋, 左金华, 王文龙, 马向瑞, 王丽. 多发性钙化上皮瘤1例及基因检测分析[J]. 中国口腔颌面外科杂志, 2023, 21(5): 526-528.